Skip to main content
Top
Published in: Diabetologia 1/2005

01-01-2005 | Article

Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy

Authors: L. Tarnow, P. Hildebrandt, B. V. Hansen, K. Borch-Johnsen, H.-H. Parving

Published in: Diabetologia | Issue 1/2005

Login to get access

Abstract

Aims/hypothesis

Raised N-terminal pro-brain natriuretic peptide (NT-proBNP) is independently associated with an increased risk of death in chronic heart failure and acute coronary syndromes in nondiabetic populations. Diabetic nephropathy is characterised by an increased risk of cardiovascular morbidity and mortality. This study investigated the prognostic value of NT-proBNP in a large cohort of type 1 diabetic patients with and without diabetic nephropathy.

Methods

In a prospective observational follow-up study, 198 type 1 diabetic patients with overt diabetic nephropathy (122 men, age [mean±SD] 41±10 years, duration of diabetes 28±8 years, GFR 74±33 ml min−1) and a matched control group of 188 patients with longstanding type 1 diabetes and persistent normoalbuminuria (114 men, age 43±10 years, duration of diabetes 27±9 years) were followed for 9.3 (0.0–9.5) years. Plasma NT-proBNP concentration was determined by immunoassay at baseline.

Results

In patients with diabetic nephropathy, plasma NT-proBNP concentration was elevated to (median [range]) 110 (5–79640) ng l−1 vs. 27 (5–455) ng l−1 in normoalbuminuric patients (p<0.0001). Among patients with nephropathy, 39 (39%) patients with plasma NT-proBNP concentrations above the median and 12 (12%) with values below the median died from any cause (unadjusted hazard ratio 3.86 [95% CI 2.02–7.37], p<0.0001; covariate-adjusted hazard ratio 2.28 [1.04–4.99], p=0.04). This lower mortality rate was attributable to fewer cardiovascular deaths: 31 (31%) and 7 (7%) above and below the median NT-proBNP level respectively (unadjusted hazard ratio 5.25 [2.31–11.92], p<0.0001; covariate-adjusted hazard ratio 3.81 [1.46–9.94], p=0.006).

Conclusions/interpretation

Elevated circulating NT-proBNP is a new independent predictor of the excess overall and cardiovascular mortality in diabetic nephropathy patients without symptoms of heart failure.
Literature
1.
go back to reference Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T (1983) Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 25:496–501PubMed Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T (1983) Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 25:496–501PubMed
2.
go back to reference Borch-Johnsen K, Andersen PK, Deckert T (1985) The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28:590–596PubMed Borch-Johnsen K, Andersen PK, Deckert T (1985) The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28:590–596PubMed
3.
go back to reference Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T (1987) Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk-factors. Diabetologia 30:144–148CrossRefPubMed Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T (1987) Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk-factors. Diabetologia 30:144–148CrossRefPubMed
4.
go back to reference de Lemos JA, McGuire DK, Drazner MH (2003) B-Type natriuretic peptide in cardiovascular disease. Lancet 362:316–322CrossRefPubMed de Lemos JA, McGuire DK, Drazner MH (2003) B-Type natriuretic peptide in cardiovascular disease. Lancet 362:316–322CrossRefPubMed
5.
go back to reference Maisel AS, Krishnaswamy P, Nowak RM et al (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161–167CrossRefPubMed Maisel AS, Krishnaswamy P, Nowak RM et al (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161–167CrossRefPubMed
6.
go back to reference Gustafsson F, Badskjær J, Hansen FS, Poulsen AH, Hildebrandt P (2003) Value of N-terminal proBNP in the diagnosis of left ventricular systolic dysfunction in primary care patients referred for echocardiography. Heart Drug 3:141–146CrossRef Gustafsson F, Badskjær J, Hansen FS, Poulsen AH, Hildebrandt P (2003) Value of N-terminal proBNP in the diagnosis of left ventricular systolic dysfunction in primary care patients referred for echocardiography. Heart Drug 3:141–146CrossRef
7.
go back to reference Groenning BA, Nilsson JC, Sondergaard L et al (2002) Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J 143:923–929CrossRefPubMed Groenning BA, Nilsson JC, Sondergaard L et al (2002) Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J 143:923–929CrossRefPubMed
8.
go back to reference Gardner RS, Özalp F, Murday AJ, Robb SD, McDonagh TA (2003) N-Terminal pro-brain natriuretic peptide—a new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24:1735–1743CrossRefPubMed Gardner RS, Özalp F, Murday AJ, Robb SD, McDonagh TA (2003) N-Terminal pro-brain natriuretic peptide—a new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24:1735–1743CrossRefPubMed
9.
go back to reference de Lemos JA, Morrow DA, Bentley JH et al (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345:1014–1021CrossRefPubMed de Lemos JA, Morrow DA, Bentley JH et al (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345:1014–1021CrossRefPubMed
10.
go back to reference Tarnow L, Cambien F, Rossing P et al (1995) Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. Diabetologia 38:798–803CrossRefPubMed Tarnow L, Cambien F, Rossing P et al (1995) Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. Diabetologia 38:798–803CrossRefPubMed
11.
go back to reference Tarnow L, Cambien F, Rossing P et al (1995) Lack of relationship between an insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 44:489–494PubMed Tarnow L, Cambien F, Rossing P et al (1995) Lack of relationship between an insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 44:489–494PubMed
12.
go back to reference Parving H-H, Østerby R, Ritz E (2003) Diabetic nephropathy. In: Brenner BM (ed) The kidney, 7th edn. WB Saunders, Philadelphia, pp 1777–1818 Parving H-H, Østerby R, Ritz E (2003) Diabetic nephropathy. In: Brenner BM (ed) The kidney, 7th edn. WB Saunders, Philadelphia, pp 1777–1818
13.
go back to reference Feldt-Rasmussen B, Dinesen B, Deckert M (1985) Enzyme immunoassay: an improved determination of urinary albumin in diabetics with incipient nephropathy. Scand J Clin Lab Invest 45:539–544PubMed Feldt-Rasmussen B, Dinesen B, Deckert M (1985) Enzyme immunoassay: an improved determination of urinary albumin in diabetics with incipient nephropathy. Scand J Clin Lab Invest 45:539–544PubMed
14.
go back to reference Bröchner-Mortensen J, Rödbro P (1976) Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 36:35–45PubMed Bröchner-Mortensen J, Rödbro P (1976) Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 36:35–45PubMed
15.
go back to reference Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461–470PubMed Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461–470PubMed
16.
go back to reference Pfeffer MA, Swedberg K, Granger CP et al (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 362:759–766CrossRefPubMed Pfeffer MA, Swedberg K, Granger CP et al (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 362:759–766CrossRefPubMed
17.
go back to reference Knowles HC, Guest GM, Lampe J, Kessler M, Skillman TG (1965) The course of juvenile diabetes treated with unmeasured diet. Diabetes 14:239–273 Knowles HC, Guest GM, Lampe J, Kessler M, Skillman TG (1965) The course of juvenile diabetes treated with unmeasured diet. Diabetes 14:239–273
18.
go back to reference Rossing P, Hougaard P, Borch-Johnsen K, Parving H-H (1996) Predictors of mortality in insulin dependent diabetes: 10 year follow-up study. Br Med J 313:779–784 Rossing P, Hougaard P, Borch-Johnsen K, Parving H-H (1996) Predictors of mortality in insulin dependent diabetes: 10 year follow-up study. Br Med J 313:779–784
19.
go back to reference Tarnow L, Rossing P, Gall M-A, Nielsen FS, Parving H-H (1994) Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 17:1247–1251PubMed Tarnow L, Rossing P, Gall M-A, Nielsen FS, Parving H-H (1994) Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 17:1247–1251PubMed
20.
go back to reference Hildebrandt P, Boesen M, Olsen MH, Wachtell K, Groenning BA (2004) N-Terminal pro brain natriuretic peptide in arterial hypertension—a marker for left ventricular dimensions and prognosis. Eur J Heart Fail 6:313–317CrossRefPubMed Hildebrandt P, Boesen M, Olsen MH, Wachtell K, Groenning BA (2004) N-Terminal pro brain natriuretic peptide in arterial hypertension—a marker for left ventricular dimensions and prognosis. Eur J Heart Fail 6:313–317CrossRefPubMed
21.
go back to reference Sato A, Tarnow L, Parving H-H (1999) Prevalence of left ventricular hypertrophy in type 1 diabetic patients with diabetic nephropathy. Diabetologia 42:76–80CrossRefPubMed Sato A, Tarnow L, Parving H-H (1999) Prevalence of left ventricular hypertrophy in type 1 diabetic patients with diabetic nephropathy. Diabetologia 42:76–80CrossRefPubMed
22.
go back to reference Epshteyn V, Mudalier S, Morrison K et al (2003) Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 26:2081–2087PubMed Epshteyn V, Mudalier S, Morrison K et al (2003) Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 26:2081–2087PubMed
23.
go back to reference Srivastava PM, Calafiore P, Burrell LM (2003) The role of BNP in the diagnosis of cardiac dysfunction in subjects with diabetes mellitus. Diabetologia 46(Suppl 2): A359 (Abstract) Srivastava PM, Calafiore P, Burrell LM (2003) The role of BNP in the diagnosis of cardiac dysfunction in subjects with diabetes mellitus. Diabetologia 46(Suppl 2): A359 (Abstract)
24.
go back to reference de Lemos JA, Morrow DA (2002) Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application? Circulation 106:2868–2870CrossRefPubMed de Lemos JA, Morrow DA (2002) Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application? Circulation 106:2868–2870CrossRefPubMed
25.
go back to reference Morrow DA, de Lemos JA, Sabatine MS et al (2003) Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol 42:1264–1272CrossRef Morrow DA, de Lemos JA, Sabatine MS et al (2003) Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol 42:1264–1272CrossRef
26.
go back to reference James SK, Lindahl B, Siegbahn A et al (2003) N-Terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease—a global utilization of strategies to open occluded arteries (GUSTO)-IV substudy. Circulation 108:275–281CrossRefPubMed James SK, Lindahl B, Siegbahn A et al (2003) N-Terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease—a global utilization of strategies to open occluded arteries (GUSTO)-IV substudy. Circulation 108:275–281CrossRefPubMed
27.
go back to reference Wang TJ, Larson MG, Levy D et al (2003) Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 108:13–16CrossRefPubMed Wang TJ, Larson MG, Levy D et al (2003) Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 108:13–16CrossRefPubMed
28.
go back to reference Candido R, Forbes JM, Thomas MC et al (2003) A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92:785–792CrossRefPubMed Candido R, Forbes JM, Thomas MC et al (2003) A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92:785–792CrossRefPubMed
29.
go back to reference Naganuma T, Sugimura K, Wada S et al (2002) The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 22:437–444CrossRefPubMed Naganuma T, Sugimura K, Wada S et al (2002) The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 22:437–444CrossRefPubMed
30.
go back to reference Wang TJ, Larson MG, Levy D et al (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350:655–663CrossRefPubMed Wang TJ, Larson MG, Levy D et al (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350:655–663CrossRefPubMed
31.
go back to reference Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355:1126–1130CrossRefPubMed Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355:1126–1130CrossRefPubMed
32.
go back to reference Mueller C, Scholer A, Laule-Kilian K et al (2004) Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350:647–654CrossRefPubMed Mueller C, Scholer A, Laule-Kilian K et al (2004) Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350:647–654CrossRefPubMed
Metadata
Title
Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy
Authors
L. Tarnow
P. Hildebrandt
B. V. Hansen
K. Borch-Johnsen
H.-H. Parving
Publication date
01-01-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1595-0

Other articles of this Issue 1/2005

Diabetologia 1/2005 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.